SUPPLEMENTARY METHODS
The selected randomization ratio of 3:1 was based on the therapeutic effect of omalizumab observed in previous open-label studies.
1,2
None of the participants were undergoing immunotherapy with environmental allergens or had received omalizumab in the past. Along the 48 randomized participants, 12 individuals fulfilling the same inclusion/exclusion criteria were recruited as mechanistic controls. These participants were not randomized and received neither omalizumab nor multifood OIT. Adverse events (AEs) were documented for the duration of the study and recorded and graded according to NCI-CTCAE version 4.03. Safety was independently monitored by an NIH medical monitor and the NIH DAIT DSMB. Allergic symptoms up to 4 hours after the dose were deemed related to the OIT dose per physician review. We suggested the use of cetirizine; however, it was not absolutely required and many participants did not take the cetirizine. We did not see any differences in safety or efficacy outcomes when participants took cetirizine. However, for all evaluations during screening and for primary and secondary endpoint measurements, participants were not taking cetirizine and cetirizine was withdrawn for at least 5 days prior to skin tests, blood tests, and food challenges.
Sample size considerations
In our phase 1 study of Xolair under the same IND (14831), 28 out of 33 participants (84%) reached 4,000 mg of each food protein by week 31 (15 weeks after discontinuing Xolair (omalizumab)) vs. none out of 43 participants (0%) having reached 4,000 mg of each food protein by week 31 in a group who received oral immunotherapy without Xolair. Based on our previous data, we expected that about 30% of placebo participants would be able to reach a dose of 2,000 mg each of 2 allergens at week 36 with no allergic reaction (primary endpoint). The table below shows the minimum detectable success rates in the placebo group for a range of success rates in the Xolair-treated group, assuming 80% power and effective sample size of 30 (out of 36) participants in the treated group and 10 (out of 12) participants in the placebo group (allowing for a possible 17% drop out rate). Note the sample size would have provided adequate power for effects lower than those anticipated on the basis of our preliminary data. Power calculations were performed assuming the use of Fisher's exact test with a two-sided significance level of 5% using the G*Power version 3.1.7 for Windows (SAS Institute, Cary, NC). For example, we expect 80% power if the pass rate is 10% in the placebo arm and 63% or better in the Xolair arm. Sample Size Scenario Table: Minimum detectable differences of proportions of patient who pass an oral food challenge 2,000 mg each of 2 allergens, between the placebo+multi OIT arm and Xolair+multi OIT arm (80% power).
Scenario
Xolair (omalizumab) + OIT Placebo + OIT  1  57%  5%  2  63%  10%  3  69%  15%  4 74% 20%
Endpoint offending food protein levels and dosing
We chose the same level of food protein (2 g) when determining the primary endpoint to quantify the extent to which a participant could increase their threshold of food desensitization over the course of the study. Dosing for omalizumab (and placebo) was in accordance with the Omalizumab Global Dosing Schedule (product insert, Genentech). 3 Eight weeks after the start of omalizumab/placebo, on the rapid initial dose escalation day (IDED), patients ingested increasing doses (5, 50, 150, 300, 625 or 1,250 mg of protein powder/flour) of the respective foods (spaced 30 minutes apart) until either the 1,250 mg dose (cumulative 2,380 mg) was tolerated or a significant reaction occurred. In this way, any starting dose of the individual foods in the combination of 2-5 foods given to a patient was no larger (in total mg of protein) than that starting dose which would have been given in an equivalent single food OIT regimen. 4, 5 Participants were then discharged to take this highest tolerated dose at home for the next 2 weeks and then returned biweekly for continued updosing and concomitant increases to the daily oral dose until a total top dose of up to 2 g of each food protein was achieved. This amounts to a total dose of 10 g for participants with 5 foods, 8 g for participants with 4 foods, 6 g for participants with 3 foods, and 4 g for participants with 2 foods. Findings from our previous phase 1 multifood OIT study suggested that there were no increased risks in safety with such rapid ingestion of multiple foods; therefore, this study was designed with similar dose levels and frequency of the multiple foods 1 . Each food chosen was administered as per IND and CMC guidelines. Multifood OIT maintenance was achieved when 2 g daily of each of the foods was ingested without symptoms.
Plasma and SPT methods
Food allergen specific IgE and IgG 4 levels to food allergen extracts were evaluated at baseline and at the end of the study using standardized methods in CLIA-approved laboratories (Thermo Fisher, CA, Johns Hopkins University, and Stanford Clinical laboratories). SPTs using validated and standardized techniques for the various foods were performed at baseline and the end of the study (week 36).
Boxplot definitions
All boxplots show the following information: The median value is the line in the box. The 'hinges' (upper and lower border of the box) represent the first and third quartile. The whiskers are the smallest and largest values after outliers are excluded. Outliers were defined as values greater than the 75th percentile plus 1·5 times the interquartile range (IQR), or less than 25th percentile minus 1·5 times the IQR.
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Supplementary efficacy data
Of the 36 participants randomized to the omalizumab arm, there were a total of 6 treatment or desensitization failures: 1 during IDED (week 8), 2 at week 16, and 3 at week 34. Of the 12 participants in the placebo arm, there were 8 treatment failures: 1 during IDED and 7 at week 16, and no desensitization failures. For the 4 placebo participants who met the primary endpoint, the AEs during the baseline double-blind, placebo-controlled food challenges (DBPCFCs) were mostly mild skin reactions at generally higher cumulative tolerated doses (CTDs) compared to other enrolled participants. In the omalizumab arm, 3 participants did not achieve maintenance dosing by week 34 (desensitization failures, figure 1). Of these 3 individuals, 2 had a viral illness as reported by their primary physician and one had abdominal pain leading to a dose decrease for 1-2 weeks. The median time to reach maintenance of 2 g of each allergen for the successes in the omalizumab arm was 18 weeks while it was 24 weeks for the successes in the placebo arm ( figure 3A) . The successes across both arms (P = 0.02, FDR adjusted P = 0·06, figure S4 ) showed different times to reach maintenance for the different numbers of foods they were ingesting (2 to 5 foods in their multifood OIT).
Cross-desensitization food challenges
Our group recently published data on the co-occurrence of: 1) cashew and pistachio, and 2) walnut and pecan allergies in individuals with food allergies. 6 To study whether OIT for cashew would also desensitize the same individual against pistachio, the multifood OIT did not include pistachio for that individual. Similarly, participants with walnut and pecan allergies were only provided walnut food protein in their multifood OIT but no pecan. Here, we refer to the desensitization against an allergenic food not given in the multifood OIT as 'cross-desensitization'. 24 (4 in the placebo arm and 20 in the omalizumab arm) of the participants who finished the study successfully (i.e., met the primary endpoint) were allergic to cashew and pistachio (positive DBPCFCs at screening) and all were successfully desensitized to cashew (negative DBPCFC for 2 g at week 36). 20 of these 24 participants (83%) also passed a DBPCFC to 2 g for pistachio at week 36 (figure 2). There were 4 individuals who did not show successful cross-desensitization (2 participants from each study arm). In addition, 17 participants (all in the omalizumab arm) who were study successes were allergic to walnut and pecan and 100% passed a 2 g DBPCFC to pecan, as well as walnut, at week 36. There was insufficient evidence to identify baseline characteristics (i.e., serum markers of specific IgE, specific IgG 4 or specific IgG 4 /specific IgE ratio (figure S10), SPT, CTD of DBPCFC, comorbid conditions) that could predict those individuals who did not successfully experience cross-desensitization for cashew-pistachio vs. those who did. Pistachio or pecan specific IgG 4 /IgE ratios ( figure S8C ) and SPT wheal diameters (figure S9A) of study successes in the omalizumab and placebo arms showed a significant increase or decrease, respectively, between baseline and week 36.
Supplementary safety data
There were no statistically significant differences between the omalizumab and placebo arms for completing the build-up phase or entire study period with only mild symptoms (secondary endpoint) (table S2) . Moreover, there were no statistically significant associations of increased AEs with any particular food in the multifood OIT, numbers of foods in the multifood OIT, sex, age, dose per body weight, total IgE, highest allergen-specific IgE at baseline, length of time with disease, or comorbid conditions (table S4) . Percent of OIT doses associated with AEs in weeks 8-16, comparing primary endpoint successes vs. failures, were not significant (figure S3). All AEs resolved with no apparent sequelae. No participants developed persistent GI symptoms (abdominal pain) or developed eosinophilic esophagitis. No participant, at any point in the study, experienced fainting, laryngeal edema, dizziness, and/or hypotension related to study drug. Treatment for AEs is displayed in table S3. A total of 9 participants (4 in the omalizumab arm and 5 in the placebo arm) used injectable epinephrine eleven times during the study for mild to moderate reactions. Each participant and their use of injectable epinephrine is documented below.
• Placebo arm: One dose of epinephrine was used in clinic at the IDED after the 1,250 mg total protein dose. The participant experienced wheezing with no shortness of breath and no difficulty breathing and was given one dose of epinephrine with immediate resolution of the wheezing.
• Placebo arm: One dose of epinephrine was administered in clinic at the IDED after the 300 mg dose.
The participant experienced somnolence but no dizziness and no hypotension.
• Placebo Arm: One dose of epinephrine was administered at home approximately 50 minutes after a dose of multifood OIT dose due to wheezing with no shortness of breath and no difficulty breathing.
• Placebo arm: One dose of epinephrine was administered in clinic at the exit DBPCFC after the 2,000 mg dose escalation. The participant experienced wheezing with no shortness of breath and no difficulty breathing.
• Placebo arm: One participant experienced two reactions at home resulting in epinephrine use. The first instance: one dose of epinephrine at home approximately 1 hour after a dose of multifood OIT due to wheezing. The second instance (separate day): one dose of epinephrine at home approximately 6 hours after a dose of multifood OIT due to pruritus. • Omalizumab arm: One dose of epinephrine given at home approximately 2 hours and 20 minutes following a dose of multifood OIT due to wheezing with no shortness of breath and no difficulty breathing.
• Omalizumab arm: One dose of epinephrine given at home approximately 35 minutes following a dose of multifood OIT due to persistent vomiting. The symptoms resolved shortly after the dose of epinephrine.
• Omalizumab arm: One dose of epinephrine was administered during a clinic visit after the 2,000 mg dose during an exit food challenge. The participant experienced wheezing with no shortness of breath and no difficulty breathing.
• Omalizumab arm: Two doses of epinephrine were administered in clinic following the 300 mg dose at the IDED. The participant experienced wheezing with no shortness of breath and no difficulty breathing and was given one dose of epinephrine and the wheezing resolved within two minutes. Approximately 10 minutes later, that participant experienced urticaria and was given a second dose of epinephrine and the urticaria fully resolved within 2 minutes. No P value met significance). "Treated" = those AEs for which treatment was given. "Moderate" = any AE of moderate severity. 
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Figure S10. Baseline immunoglobulin levels for cross-desensitization between cashew and pistachio
Baseline IgE (A), IgG4 (B) and IgG 4 :IgE ratio (C) for study successes, stratified by cashew and pistachio as well as by successful cross-desensitization (i.e., desensitization against pistachio, which was not given in the multifood OIT) and those who had a positive DBPCFC to pistachio at week 36 (i.e., no crossdesensitization). No P value met significance. Data are in median (1 st , 3 rd quartile), n (%). ^ The age of diagnosis per participant is determined by the median of the ages of diagnosis of the different food allergies. * Odds ratios (OR) were estimated based on unconditional maximum likelihood estimation.
